Of this total, 1,239 deaths and 50,872 positive cases were recorded in the last 24 hours, the fourth consecutive day on which the South American country recorded more than 50 thousand diagnoses and one thousand fatalities due to covid-19.
Along with the United States and India, Brazil, the Portuguese-speaking country most affected by the pandemic, becomes the third nation in the world to surpass the 9.4 million diagnoses of covid-19.
The mortality rate of the disease in Brazil remains at 2.4% and the incidence rate is now 109 deaths and 4,496 cases per 100 thousand inhabitants.
São Paulo remains the focus of the pandemic in the country, concentrating 1,833,163 infections detected, followed by the States of Minas Gerais (762,412), Bahia (602,792) and Santa Catarina (590,449).
Regarding the number of deaths, the list continues to be led by São Paulo, the most populous state in the country, with 54,324 deaths, followed by Rio de Janeiro (30,545), Minas Gerais (15,667) and Rio Grande do Sul (10,929) ).
Brazil is the third country in the world where most people recover from the disease (8,326,798), with 890,333 infected patients remaining under medical supervision.
The day after the Brazilian Senate approved a provisional measure that eases the emergency use of vaccines against covid-19, the president of the National Health Surveillance Agency (Anvisa, Brazil’s regulatory agency), Antônio Barra Torres, said the new The five-day deadline for vaccine approval in the country is “unreal”.
“This deadline was defined today by our general manager of medicines, Gustavo Mendes, as an unrealistic deadline. I fully share his opinion. This term is a term that, even, we do not know where it comes from ”, criticized the president of Anvisa in an interview with the Globo network.
Antônio Barra Torres considered that the text approved by the Senate poses a risk to public health and that the established deadline is not feasible for a safe analysis of vaccines.
The president of Anvisa also said that, currently, the period of 10 days is considered adequate for analyzing requests for emergency use of vaccines.
Anvisa considers filing a lawsuit in the Federal Supreme Court (STF) to block the measure approved in Congress and also prepares a document to send to the Ministry of Civil Affairs, requesting the presidential veto of the head of state, Jair Bolsonaro, to the segment of the provisional measure fixing the analysis period at five days for vaccines already approved in other countries.
According to the provisional measure, which is now going to the presidential evaluation, the condition for the rules to be relaxed is that the use of the vaccine has already been authorized by other international authorities, as is the case of the American Food and Medicines Agency ( FDA, and the European Medicines Agency (EMA).
–
